Clinical Trial: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07519070) titled 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis' on March 31.

Brief Summary: This study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).

Study Start Date: April 05

Study Type: INTERVENTIONAL

Condition: IPF

Intervention: DRUG: HSK44459

HSK44459 Without IPF background therapy

DRUG: HSK44459

HSK44459 With Nintedanib

DRUG: HSK44459

HSK44459 With Pirfenidone

DRUG: Placebo

Placebo Without IPF background therapy

DRUG: Placebo

Plac...